Deciphera Pharmaceuticals (NASDAQ:DCPH) stock absolutely imploded in November. Shares lost more than two-thirds of their value virtually overnight. Source: Iryna Imago / Shutterstock.com DCPH stock ...

Deciphera Pharmaceuticals, Inc. DCPH currently looks like a good stock from the biotech sector to invest in. Though smaller biotech companies are riskier as their product pipelines are several years ...

On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...

Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO Pharmaceutical’s Pipeline ...

Japan’s Ono Pharmaceutical described Deciphera's portfolio as a “mature, diverse pipeline of best-or-first in class potential medicines.” (Stock photo/Getty Images) Japan’s Ono Pharmaceutical is ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

WALTHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance ...

With a restructuring, Deciphera CEO Steve Hoerter said the Massachusetts biopharma has “a clear and positive path forward." (Deciphera) () A devastating trial flop for Deciphera's gastrointestinal ...

Deciphera has a strong portfolio of investigational kinase inhibitors, including ripretinib, vimseltinib, and DCC-3116, that have demonstrated encouraging preliminary efficacy and safety data in ...

Deciphera is moving to launch Qinlock this week. Analysts predict it could be worth as much as $1.6 billion in revenue this year. "With [Qinlock's] phase 1 looking better than sunitinib, it has a good ...